Arena Pharmaceuticals (ARNA - Get Report) CEO Jack Lief sold just under 40% of his company stock holdings last week, according to an SEC filing Thursday.
Lief sold 223,525 shares of Arena stock at an average price of $5.85 per share, which grossed him $1.3 million, according to the Form 4 filing. Lief's divestment of Arena shares was done under a pre-arranged 10b5-1 trading plan, the filing also noted.
We can debate whether insider selling under 10b5-1 plans is really "hands off" or not (I tend to be a skeptic because these pre-arranged trading plans can be manipulated) but the optics of Lief's stock sale look bad given the significant under-performance of Arena's stock price amidst disappointing sales of the company's obesity pill Belviq. Lief dumping 40% of his Arena shares all at once when the stock is hitting new lows isn't exactly confidence inspiring.
Arena shares are down 8.5% to $5.34 in Monday trading.
On a related note, I guess we can now put to rest any hope that Eisai is planning to acquire Arena. Lief wouldn't be selling if there was any truth to the takeover conjecture floated in May.
With today's sell-off, Arena's stock performance year to date looks even worse:
ARNA data by YCharts
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/04/16 - 18:23 PM EDT
05/04/16 - 17:09 PM EDT
05/04/16 - 16:49 PM EDT
05/04/16 - 16:24 PM EDT
05/04/16 - 14:38 PM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.